HM Capital Management LLC Buys 379 Shares of Johnson & Johnson (NYSE:JNJ)

HM Capital Management LLC boosted its stake in Johnson & Johnson (NYSE:JNJ) by 2.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,433 shares of the company’s stock after purchasing an additional 379 shares during the quarter. Johnson & Johnson comprises about 1.2% of HM Capital Management LLC’s investment portfolio, making the stock its 15th largest holding. HM Capital Management LLC’s holdings in Johnson & Johnson were worth $1,867,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Phocas Financial Corp. increased its holdings in shares of Johnson & Johnson by 999,928.6% in the second quarter. Phocas Financial Corp. now owns 125,173,583 shares of the company’s stock worth $1,743,000 after acquiring an additional 125,161,066 shares in the last quarter. Nuveen Asset Management LLC increased its holdings in shares of Johnson & Johnson by 5,447.1% in the second quarter. Nuveen Asset Management LLC now owns 16,924,656 shares of the company’s stock worth $2,357,266,000 after acquiring an additional 16,619,550 shares in the last quarter. Thoroughbred Financial Services LLC increased its holdings in shares of Johnson & Johnson by 14,147.0% in the second quarter. Thoroughbred Financial Services LLC now owns 4,014,247 shares of the company’s stock worth $401,425,000 after acquiring an additional 3,986,071 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of Johnson & Johnson by 145.5% in the second quarter. Renaissance Technologies LLC now owns 4,341,162 shares of the company’s stock worth $604,637,000 after acquiring an additional 2,572,695 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Johnson & Johnson by 11.9% in the second quarter. Price T Rowe Associates Inc. MD now owns 20,791,713 shares of the company’s stock worth $2,895,870,000 after acquiring an additional 2,204,757 shares in the last quarter. Institutional investors and hedge funds own 72.05% of the company’s stock.

Several equities research analysts have issued reports on JNJ shares. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Wells Fargo & Co lowered their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a report on Wednesday. Credit Suisse Group increased their price target on Johnson & Johnson from $156.00 to $158.00 and gave the stock an “outperform” rating in a report on Wednesday. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 price target for the company in a report on Thursday. Finally, Atlantic Securities upgraded Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $151.18.

JNJ stock opened at $127.70 on Friday. The stock has a 50-day moving average price of $130.45 and a 200-day moving average price of $134.76. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46. The firm has a market cap of $359.38 billion, a PE ratio of 15.53, a price-to-earnings-growth ratio of 2.30 and a beta of 0.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.54% and a net margin of 21.09%. Johnson & Johnson’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.05 earnings per share. On average, analysts forecast that Johnson & Johnson will post 8.65 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a yield of 2.98%. Johnson & Johnson’s payout ratio is 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Story: How Do Front-End Loads Impact an Investment?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.